Briefly, somatic mutations affecting the R132 residue of the isocitrate dehydrogenase 1 (IDH1) or R172 residue of the isocitrate dehydrogenase 2 gene (IDH2) are often detected in WHO grade II or III gliomas and oligodendrogliomas. This evidence concerns the gene IDH2 and glioma.